February 23, 2023 10:31 AM EST
R&D
Cell/Gene Tx

Sick­le cell R&D hit by three culls in one day at No­var­tis/In­tel­lia, Sang­amo and Graphite Bio

Kyle LaHucik

Senior Reporter

Three biotechs dis­closed pull­backs on sick­le cell dis­ease R&D in the span of 16 hours: with Graphite Bio end­ing work, Sang­amo Ther­a­peu­tics search­ing for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK leaves biotech trade group BIO

Am­gen and As­traZeneca share pos­i­tive re­sults in chron­ic rhi­nos­i­nusi­tis

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

FDA records re­quest lands Chi­nese API man­u­fac­tur­er on blocked im­port list

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times